000169886 001__ 169886
000169886 005__ 20240229133659.0
000169886 0247_ $$2doi$$a10.1001/jamainternmed.2021.3836
000169886 0247_ $$2pmid$$apmid:34279548
000169886 0247_ $$2ISSN$$a0003-9926
000169886 0247_ $$2ISSN$$a0730-188X
000169886 0247_ $$2ISSN$$a0888-2479
000169886 0247_ $$2ISSN$$a1538-3679
000169886 0247_ $$2ISSN$$a2168-6106
000169886 0247_ $$2ISSN$$a2168-6114
000169886 0247_ $$2ISSN$$a2375-6799
000169886 0247_ $$2altmetric$$aaltmetric:109941220
000169886 037__ $$aDKFZ-2021-01620
000169886 041__ $$aEnglish
000169886 082__ $$a610
000169886 1001_ $$aRied-Larsen, Mathias$$b0
000169886 245__ $$aAssociation of Cycling With All-Cause and Cardiovascular Disease Mortality Among Persons With Diabetes: The European Prospective Investigation Into Cancer and Nutrition (EPIC) Study.
000169886 260__ $$aChicago, Ill.$$bAmerican Medical Association$$c2021
000169886 3367_ $$2DRIVER$$aarticle
000169886 3367_ $$2DataCite$$aOutput Types/Journal article
000169886 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642168890_14743
000169886 3367_ $$2BibTeX$$aARTICLE
000169886 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169886 3367_ $$00$$2EndNote$$aJournal Article
000169886 500__ $$a2021 Sep 1;181(9):1196-1205
000169886 520__ $$aPremature death from all causes and cardiovascular disease (CVD) causes is higher among persons with diabetes.To investigate the association between time spent cycling and all-cause and CVD mortality among persons with diabetes, as well as to evaluate the association between change in time spent cycling and risk of all-cause and CVD mortality.This prospective cohort study included 7459 adults with diabetes from the European Prospective Investigation into Cancer and Nutrition study. Questionnaires regarding medical history, sociodemographic, and lifestyle information were administered in 10 Western European countries from 1992 through 2000 (baseline examination) and at a second examination 5 years after baseline. A total of 5423 participants with diabetes completed both examinations. The final updated primary analysis was conducted on November 13, 2020.The primary exposure was self-reported time spent cycling per week at the baseline examination. The secondary exposure was change in cycling status from baseline to the second examination.The primary and secondary outcomes were all-cause and CVD mortality, respectively, adjusted for other physical activity modalities, diabetes duration, and sociodemographic and lifestyle factors.Of the 7459 adults with diabetes included in the analysis, the mean (SD) age was 55.9 (7.7) years, and 3924 (52.6%) were female. During 110 944 person-years of follow-up, 1673 deaths from all causes were registered. Compared with the reference group of people who reported no cycling at baseline (0 min/wk), the multivariable-adjusted hazard ratios for all-cause mortality were 0.78 (95% CI, 0.61-0.99), 0.76 (95% CI, 0.65-0.88), 0.68 (95% CI, 0.57-0.82), and 0.76 (95% CI, 0.63-0.91) for cycling 1 to 59, 60 to 149, 150 to 299, and 300 or more min/wk, respectively. In an analysis of change in time spent cycling with 57 802 person-years of follow-up, a total of 975 deaths from all causes were recorded. Compared with people who reported no cycling at both examinations, the multivariable-adjusted hazard ratios for all-cause mortality were 0.90 (95% CI, 0.71-1.14) in those who cycled and then stopped, 0.65 (95% CI, 0.46-0.92) in initial noncyclists who started cycling, and 0.65 (95% CI, 0.53-0.80) for people who reported cycling at both examinations. Similar results were observed for CVD mortality.In this cohort study, cycling was associated with lower all-cause and CVD mortality risk among people with diabetes independent of practicing other types of physical activity. Participants who took up cycling between the baseline and second examination had a considerably lower risk of both all-cause and CVD mortality compared with consistent noncyclists.
000169886 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169886 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169886 7001_ $$aRasmussen, Martin Gillies$$b1
000169886 7001_ $$aBlond, Kim$$b2
000169886 7001_ $$aOvervad, Thure F$$b3
000169886 7001_ $$aOvervad, Kim$$b4
000169886 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$udkfz
000169886 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b6$$udkfz
000169886 7001_ $$aAndersen, Julie L M$$b7
000169886 7001_ $$aPetersen, Kristina E N$$b8
000169886 7001_ $$aAune, Dagfinn$$b9
000169886 7001_ $$aTsilidis, Kostas K$$b10
000169886 7001_ $$aHeath, Alicia K$$b11
000169886 7001_ $$aPapier, Keren$$b12
000169886 7001_ $$aPanico, Salvatore$$b13
000169886 7001_ $$aMasala, Giovanna$$b14
000169886 7001_ $$aPala, Valeria$$b15
000169886 7001_ $$aWeiderpass, Elisabete$$b16
000169886 7001_ $$aFreisling, Heinz$$b17
000169886 7001_ $$aBergmann, Manuela M$$b18
000169886 7001_ $$aVerschuren, W M Monique$$b19
000169886 7001_ $$aZamora-Ros, Raul$$b20
000169886 7001_ $$aColorado-Yohar, Sandra M$$b21
000169886 7001_ $$aSpijkerman, Annemieke M W$$b22
000169886 7001_ $$aSchulze, Matthias B$$b23
000169886 7001_ $$aArdanaz, Eva M A$$b24
000169886 7001_ $$aAndersen, Lars Bo$$b25
000169886 7001_ $$aWareham, Nick$$b26
000169886 7001_ $$aBrage, Søren$$b27
000169886 7001_ $$aGrøntved, Anders$$b28
000169886 773__ $$0PERI:(DE-600)2699342-9$$a10.1001/jamainternmed.2021.3836$$n9$$p1196-1205$$tJAMA internal medicine$$v181$$x2168-6106$$y2021
000169886 909CO $$ooai:inrepo02.dkfz.de:169886$$pVDB
000169886 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000169886 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000169886 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169886 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169886 9141_ $$y2021
000169886 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA INTERN MED : 2019$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000169886 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bJAMA INTERN MED : 2019$$d2021-01-30
000169886 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000169886 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000169886 980__ $$ajournal
000169886 980__ $$aVDB
000169886 980__ $$aI:(DE-He78)C110-20160331
000169886 980__ $$aI:(DE-He78)C020-20160331
000169886 980__ $$aUNRESTRICTED